Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Tianjin Tasly Out-licenses US Rights to TCM Angina Drug in $50 Million Deal

publication date: Sep 11, 2018

Tianjin Tasly Pharma out-licensed US marketing rights for compound Danshen dripping pills, a TCM for angina, to Arbor Pharma. Arbor will pay up to $23 million upfront to underwrite the US Phase III trial of Danshen. Ultimately, if Danshen is approved, Arbor will pay $50 million for Danshen rights plus 50% of its gross profit from the drug to Tasly's US subsidiary. Tasly pointed out that Danshen is the first TCM to ever complete a US Phase III trial, though results are not published. More details....

Stock Symbol: (SHA: 600535)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.